A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam Administered as a Two-drug Cocktail in Patients With ALK-positive Advanced Tumors Including Non-small Cell Lung Cancer (NSCLC)

Trial Profile

A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam Administered as a Two-drug Cocktail in Patients With ALK-positive Advanced Tumors Including Non-small Cell Lung Cancer (NSCLC)

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Nov 2017

At a glance

  • Drugs Ceritinib (Primary) ; Midazolam; Warfarin
  • Indications Non-small cell lung cancer
  • Focus Pharmacokinetics
  • Sponsors Novartis
  • Most Recent Events

    • 09 Nov 2017 Planned End Date changed from 22 Sep 2017 to 23 Nov 2017.
    • 09 Nov 2017 Planned primary completion date changed from 22 Sep 2017 to 23 Nov 2017.
    • 09 Nov 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top